We Are Still Not Independent of Foreign Drug Firms (Phillipines)
This article was originally published in PharmAsia News
Executive Summary
The Philippines has the second most expensive pharmaceutical drug prices in Asia behind Japan, far higher than prices found in China, Singapore, Hong Kong, India, Malaysia, and other Asian nations, writes Neal Cruz. One main reason is that the Philippines awards brand-name drugs 25-year exclusive patents, and many people in the country cannot afford Western-level or Japan-level prices. In addition, foreign firms won 2,097 patents in the Philippines between 2001 and 2005, while native drug companies won a single patent. In terms of pricing, hypertension drug Norvasc sells for 41.41 pesos per 5-mg tablet in the Philippines. In India the same drug by the same company sells for 5.77 pesos per tablet. A Ventolin inhaler for asthmatics costs 315 pesos in the Philippines and 126.78 pesos in India. The Philippines has a 85 billion peso drug market. The government should make a greater effort to import low-cost medicines, and should boost funding for Philippine International Trading to import and produce low-cost drugs, argues Cruz. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.